Orthocell Ltd

#Orthocell has announced that it has appointed Device Technologies | Asia as the exclusive distributor of market leading peripheral nerve repair device Remplir™ in Singapore. This agreement extends a very successful distribution partnership with Device Technologies which distributes Remplir in Australia and New Zealand, where sales have grown rapidly since launch. Singapore is the first major international market launch outside the existing markets of Australia and New Zealand. It is a strategic jurisdiction, both as a destination for sophisticated medical treatments in the region and as a regulatory gateway to other substantial ASEAN markets, in a global nerve repair market estimated to exceed US$3.5 billion. Orthocell CEO and MD, Paul Anderson, said: “Device Technologies Asia is a leading supplier of innovative medical solutions to hospitals and healthcare professionals throughout Singapore and South East Asia. We are delighted to extend our very successful distribution partnership with Device Technologies in Australia and New Zealand into Singapore. They have a proven track record in successfully driving the market entry of high-quality products with specialist capabilities and resources, and in the marketing, promotion and distribution of Remplir™. We are very much looking forward to working with DVT Asia to establish Remplir as the highest quality nerve repair device in Singapore. We expect revenue growth and surgeon adoption of Remplir to accelerate from market launch in Q1 CY25.” Read the ASX release 👉 https://lnkd.in/gY-WJgZ3 $OCC #innovation #medtech #regenerativemedicine #nerverepair #Singapore

Orthocell Ltd CEO & MD Paul Anderson joined Australia's biotech and medtech leaders at the inaugural National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra this week. The summit brought together over 100 of Australia's leading industry figures, policy experts, and innovators to address critical challenges in commercialising Australian medical innovations. As a Company committed to advancing regenerative medicine – and the wider life sciences sector – Orthocell was excited to be part of this national conversation on strengthening Australia's position in the global biotech landscape. Key summit themes included protecting Australia's sovereign capabilities, accelerating commercialisation pathways, optimising capital deployment, and developing our future workforce – all crucial elements in bridging Australia's research-to-market gap. Following the summit, Orthocell was the only company invited to present a case study at the parliamentary function, where Paul showcased our journey in bringing Australian innovations to global markets. Thank you to AusBiotech and MTPConnect for organising this important industry event. We look forward to contributing to the sector's growth and bringing more Australian innovations to global markets.  $OCC #biotech #medtech #innovation #healthcare #regenerativemedicine #leadership 

📺 STOCKHEAD INTERVIEW This week Orthocell Ltd announced the appointment of two new US-based executives as the Company prepares to enter the US market with its nerve repair product, Remplir™. Orthocell Chairman John Van Der Wielen spoke with Stockhead to share insights into why Remplir represents a compelling investment opportunity. Here's an excerpt: "The difference between Orthocell is you've got a product that's already been used in human bodies. There's over $35 million of cash on the balance sheet, and it's already in revenue with existing regulatory approval. It has crossed that threshold between this amazing concept and something that's actually generating revenue... it's a very low risk biotech compared to the majority of other smaller cap stocks. People are realising this is right on the threshold of coming into profit and significant growth." It's worth a look 👉 https://lnkd.in/giyF7DWT $OCC #Orthocell #nerverepair #medicaldevice #healthcare #medtech #innovation #growth #invest

📺 𝐌𝐞𝐞𝐭 𝐓𝐡𝐞 𝐁𝐨𝐚𝐫𝐝 | 𝐈𝐧𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫, 𝐃𝐫. 𝐑𝐚𝐯𝐢 𝐓𝐡𝐚𝐝𝐡𝐚𝐧𝐢 The fourth episode of Orthocell's 'Meet the Board' video series is now live - featuring Independent Director, Dr. Ravi Thadhani MD, MPH. As a physician-scientist with 30 years of research experience and a decade as an FDA consultant, Dr. Thadhani brings unique insights into both the clinical and regulatory aspects of Orthocell's journey. He shares his perspectives on why Remplir™ represents a significant advancement in addressing unmet medical needs while reducing complications associated with current nerve repair treatments. Reflecting on what makes Orthocell such an exciting Company at this time: “𝘐𝘧 𝘰𝘯𝘦 𝘢𝘴𝘬𝘴 𝘵𝘩𝘦 𝘲𝘶𝘦𝘴𝘵𝘪𝘰𝘯, 𝘸𝘩𝘢𝘵 𝘴𝘩𝘰𝘶𝘭𝘥 𝘢𝘯𝘺𝘰𝘯𝘦 𝘰𝘯 𝘵𝘩𝘦 𝘰𝘶𝘵𝘴𝘪𝘥𝘦 𝘣𝘦 𝘭𝘰𝘰𝘬𝘪𝘯𝘨 𝘢𝘵? - 𝘠𝘰𝘶'𝘳𝘦 𝘭𝘰𝘰𝘬𝘪𝘯𝘨 𝘧𝘰𝘳 𝘢𝘯 𝘰𝘶𝘵𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘉𝘰𝘢𝘳𝘥, 𝘢𝘯 𝘰𝘶𝘵𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘵𝘦𝘢𝘮, 𝘢𝘯𝘥 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵𝘭𝘺 𝘢𝘯 𝘰𝘶𝘵𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘵𝘩𝘢𝘵 𝘮𝘢𝘬𝘦𝘴 𝘢 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘪𝘯 𝘭𝘪𝘷𝘦𝘴. 𝘈𝘯𝘥 𝘖𝘳𝘵𝘩𝘰𝘤𝘦𝘭𝘭 𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘭𝘺 𝘣𝘳𝘪𝘯𝘨𝘴 𝘢𝘭𝘭 𝘵𝘩𝘳𝘦𝘦 𝘵𝘰 𝘵𝘩𝘦 𝘵𝘢𝘣𝘭𝘦.” Watch it here 👉 https://lnkd.in/g5cQ6ehg $OCC #Orthocell #regenerativemedicine #leadership #biotech #healthcare #MeetTheBoard

⭐ Executive Appointments ⭐ Orthocell Ltd has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US FDA approval in the first quarter of 2025. John Walker joins the team as Vice President – Sales. Mr Walker is a highly experienced sales executive, who has successfully led global product launches and sales strategies, most notably helping to lead the growth of nerve repair device sales at Axogen. Orthocell also welcomes Phillip Edmondson, Vice President - Medical Affairs. Mr Edmondson is an award-winning medical affairs professional, who excels in creating product awareness, building advocacy and implementing successful medical education programs that contribute to sales growth. Orthocell CEO and MD, Paul Anderson, said:  “The USA provides a significant opportunity for our company as a circa $US 1.6 billion market, and our belief is that it will quickly become our single largest market…We are delighted to have John and Phillip join us to lead the US launch and are excited about the next phase of growth. With all the preparation we’ve been conducting in the background, we expect revenue growth and surgeon adoption of Remplir to accelerate from market clearance.” Orthocell remains on schedule to release top-line results from its Remplir US market authorisation study and submit its Remplir US 510(K) application in Q4 CY24. Read the ASX release 👉 https://lnkd.in/gPcNjWMG $OCC #innovation #nerverepair #regenerativemedicine #executive #leadership #growth #medtech

🎙️ Equity Mates Podcast #Orthocell has been named as a biotech stock to watch on a recent episode the Equity Mates Investing Podcast. Michael Frazis, founder of Frazis Capital Partners, mentions Orthocell’s recent capital raise and plans for expansion into the US market, highlighting the Company’s opportunity to achieve substantial growth. Have a listen (segment starts at 28:43) 👉 https://lnkd.in/gyHDR7_U $OCC #biotech #healthcare #invest #regenerativemedicine

Orthocell Ltd has today announced that it has successfully completed a $17 million placement to fund the US launch of Remplir™ and to drive further global commercialisation for both Remplir and Striate+™. The Placement received very strong support, and the Company emerges with a strong balance sheet with circa $35 million in cash and no debt to be applied towards funding the launch of Remplir in the United States and other key markets including Singapore, Southeast Asia, Canada and the EU/UK. Orthocell Chair, John Van Der Wielen, said: “This successful capital raise represents strong market validation of Orthocell’s growth potential and commercial strategy. This allows us to grow the USA market quicker, invest in volume manufacturing, and also speed up the progress of our promising pipeline products. The Board and I would like to welcome the new investors to the register.” Read the ASX release 👉 https://lnkd.in/gx3_EEkB $OCC #Orthocell #innovation #regenerativemedicine #medtech #innovation #nerve #growth #capitalraise

💰 Capital Raise #Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement. Funds raised are expected to fully fund the launch of Remplir into the key US$1.6 billion US market, along with expansion into other key markets including Singapore, Southeast Asia, Canada and the EU and UK. The Placement was led by Canaccord Genuity. Orthocell Chair, John Van Der Wielen, said: “We are extremely pleased to announce this significant Placement following on from our second consecutive quarter of record revenue, regulatory approval of Remplir in Singapore, successful first sales of Striate in Canada, and the exciting outlook for the Company as it progresses approvals in new key jurisdictions like the US. This allows us to grow the USA market quicker, invest in volume manufacturing and also speed up the progress of our promising pipeline products. The Board and I would like to welcome the new investors to the register.” Read the ASX release 👉 https://lnkd.in/gRUueYeH $OCC #Orthocell #innovation #regenerativemedicine #medtech #innovation #nerve #growth #captialraise

📺 𝐌𝐞𝐞𝐭 𝐓𝐡𝐞 𝐁𝐨𝐚𝐫𝐝 | 𝐂𝐡𝐚𝐢𝐫𝐦𝐚𝐧, 𝐉𝐨𝐡𝐧 𝐕𝐚𝐧 𝐃𝐞𝐫 𝐖𝐢𝐞𝐥𝐞𝐧 The third episode of Orthocell’s ‘Meet the Board’ video series is now online - featuring Orthocell Chairman, John Van Der Wielen. Drawing on over 30 years’ experience in executive leadership roles, John shares his vision for Orthocell's groundbreaking nerve repair technology and its potential to transform patient outcomes while reducing healthcare costs, particularly as the Company expands into the significant US market. Here’s an excerpt: “𝘞𝘦'𝘳𝘦 𝘢𝘵 𝘵𝘩𝘦 𝘱𝘩𝘢𝘴𝘦 𝘸𝘩𝘦𝘳𝘦 𝘵𝘩𝘦 𝘊𝘰𝘮𝘱𝘢𝘯𝘺 𝘸𝘪𝘭𝘭 𝘵𝘢𝘬𝘦 𝘰𝘧𝘧. 𝘈𝘵 𝘵𝘩𝘪𝘴 𝘴𝘵𝘢𝘨𝘦, 𝘪𝘯𝘷𝘦𝘴𝘵𝘰𝘳𝘴 𝘢𝘳𝘦 𝘨𝘦𝘵𝘵𝘪𝘯𝘨 𝘪𝘯𝘵𝘰 𝘴𝘰𝘮𝘦𝘵𝘩𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘢 𝘳𝘦𝘭𝘢𝘵𝘪𝘷𝘦𝘭𝘺 𝘭𝘰𝘸 𝘮𝘢𝘳𝘬𝘦𝘵 𝘤𝘢𝘱, 𝘢𝘯 𝘦𝘹𝘵𝘳𝘦𝘮𝘦𝘭𝘺 𝘴𝘵𝘳𝘰𝘯𝘨 𝘉𝘰𝘢𝘳𝘥, 𝘢𝘯𝘥 𝘸𝘦'𝘳𝘦 𝘢𝘣𝘰𝘶𝘵 𝘵𝘰 𝘦𝘯𝘵𝘦𝘳 𝘵𝘩𝘦 𝘜𝘚 𝘮𝘢𝘳𝘬𝘦𝘵. 𝘐𝘵'𝘴 𝘢 𝘤𝘰𝘮𝘱𝘦𝘭𝘭𝘪𝘯𝘨 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘧𝘰𝘳 𝘢𝘯𝘺𝘰𝘯𝘦 𝘸𝘩𝘰 𝘸𝘪𝘴𝘩𝘦𝘴 𝘵𝘰 𝘨𝘦𝘵 𝘪𝘯𝘵𝘰 𝘵𝘩𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘣𝘶𝘴𝘪𝘯𝘦𝘴𝘴, 𝘢𝘯𝘥 𝘵𝘩𝘦𝘳𝘦 𝘢𝘳𝘦𝘯'𝘵 𝘮𝘢𝘯𝘺 𝘭𝘪𝘴𝘵𝘦𝘥 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢𝘯 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴 𝘵𝘩𝘢𝘵 𝘩𝘢𝘷𝘦 𝘵𝘩𝘪𝘴 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭."   Watch it here 👉 https://lnkd.in/gXgQEUCX $OCC #Orthocell #regenerativemedicine #leadership #biotech #healthcare #MeetTheBoard

🌏 Celebrating World Food Day Yesterday our team came together for our annual World Food Day celebration, bringing dishes that tell the stories of their heritage. With over 20 nationalities represented at Orthocell, each dish represented not just a recipe, but a piece of someone's history and identity. At Orthocell, we believe that the best breakthroughs happen when diverse minds come together. Our multinational team brings together different perspectives, experiences, and problem-solving approaches that drive our innovation in regenerative medicine.   It is this diversity that fuels our success, allowing us to push boundaries and transform the lives of patients worldwide.   $OCC #Orthocell #innovation #medtech #regenerativemedicine #global